Molecular Formula | C24H18N4O |
Molar Mass | 378.43 |
Density | 1.41±0.1 g/cm3(Predicted) |
Melting Point | >221°C (dec.) |
Boling Point | 652.3±55.0 °C(Predicted) |
Solubility | Acetonitrile (Very Slightly, Heated), DMSO (Slightly), Methanol (Very Slightly, |
Appearance | Off-white solid |
Color | White to Off-White |
pKa | 14.39±0.20(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
In vitro study | Go6976 had no effect on the kinase activity of the Ca(2 +)-Independent PKC subtypes δ,ε, and ζ. In addition to WT JAK2,Go6976 also inhibits mutant hematological malignancies (JAK2 V617F and TEL-JAK2) and has activity against mutant FLT3. In AML cells, Go6976 reduced the viability in FLT3-ITD of the samples to 55% of the control and 69% in FLT3-WT. Go 6976 effectively inhibited Bryostatin 1, tumor necrosis factor alpha and interleukin 6 induced by HIV-1. |
In vivo study | Go 6976 (2.5 mg/kg I. p.), as a PKD inhibitor, it effectively prevents acute liver injury induced by LPS/D:-GalN by inhibiting the activation of MAPKs to reduce the production of TNF-α, and significantly improve the survival rate of mice LPS/D-GalN Aggression. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |